Published in Philos Trans R Soc Lond B Biol Sci on May 29, 2006
Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med (2008) 3.49
The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol (2006) 2.70
Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell Res (2007) 1.83
The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest (2007) 1.67
Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes (2013) 1.24
Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol (2011) 1.19
VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost. J Cell Physiol (2012) 1.00
Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hypertens (2013) 0.84
Vascular effects of prostacyclin: does activation of PPARδ play a role? Trends Pharmacol Sci (2012) 0.82
The role of exercise on L-arginine nitric oxide pathway in chronic heart failure. Open Biochem J (2009) 0.81
Role of Tie1 in shear stress and atherosclerosis. Trends Cardiovasc Med (2011) 0.79
Adenosine and blood platelets. Purinergic Signal (2011) 0.79
Vimentin and laminin are altered on cheek pouch microvessels of streptozotocin-induced diabetic hamsters. Clinics (Sao Paulo) (2011) 0.77
Blood flow modulation of vascular dynamics. Curr Opin Lipidol (2015) 0.76
Pannexin channel and connexin hemichannel expression in vascular function and inflammation. BMC Cell Biol (2017) 0.75
Effect of oral carbohydrate with amino acid solution on serum oxidative/anti-oxidative status in healthy volunteers. J Anesth (2017) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Free radicals in the physiological control of cell function. Physiol Rev (2002) 19.62
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A (1990) 16.34
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A (1987) 14.22
Hydroperoxide metabolism in mammalian organs. Physiol Rev (1979) 14.13
Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res (2000) 10.95
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A (1975) 10.82
Mitochondrial formation of reactive oxygen species. J Physiol (2003) 10.73
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature (1995) 9.86
THE USE OF ISOLATED ORGANS FOR DETECTING ACTIVE SUBSTANCES IN THE CIRCULATING BLOOD. Br J Pharmacol Chemother (1964) 9.77
Nitric oxide synthases: structure, function and inhibition. Biochem J (2001) 9.73
Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science (1987) 8.98
Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature (1988) 8.56
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A (1991) 8.04
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A (1974) 7.00
Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol (1971) 6.97
Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol (1989) 6.87
Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science (2003) 6.66
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest (1996) 6.38
Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature (1973) 6.34
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med (2005) 6.32
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 6.13
Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. Proc Natl Acad Sci U S A (1987) 5.69
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature (1990) 5.57
The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med (2001) 5.29
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A (1991) 5.07
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest (1989) 5.01
Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A (1998) 4.94
Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol (1972) 4.91
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol (1986) 4.88
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta (1973) 4.45
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci U S A (1973) 4.43
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Flow effects on prostacyclin production by cultured human endothelial cells. Science (1985) 4.15
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A (1996) 3.93
Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science (2003) 3.91
Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res (2001) 3.89
Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett (1994) 3.75
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol (1986) 3.66
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
The effects of L-arginine and NG-monomethyl L-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br J Pharmacol (1989) 3.50
The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest (1975) 3.40
Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol (2002) 3.38
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem (1990) 3.34
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. Pharmacology (1971) 3.12
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 3.07
Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation (2001) 3.01
Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol (2003) 2.96
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci U S A (2001) 2.89
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 2.61
Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60
Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun (1990) 2.55
Nitric oxide and the vascular endothelium. Handb Exp Pharmacol (2006) 1.70